EDMONTON, Nov. 2 /PRNewswire-FirstCall/ - BioMS Medical Corp , a leading developer in the treatment of multiple sclerosis (MS), today announced that the University of Alberta has received additional patents for the Company’s synthetic peptide therapeutic, MBP8298, for the treatment of multiple sclerosis (MS). BioMS Medical licenses these patents on an exclusive worldwide basis from the University of Alberta.
The most recent patent, entitled “Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient” has been granted in the United States and addresses methods of predicting efficacy of certain courses of treatment for MS patients.
“We are pleased about our recent patent protection in the United States. Protection of the Company’s intellectual property, in the United States and throughout the world, represents a key aspect of our commercial development. It also provides a view into the excellent scientific and clinical development supporting this important MS drug.” said Kevin Giese, President and CEO of BioMS Medical.
In total, BioMS has exclusive licenses to 99 granted patents in 34 countries throughout the world.
About BioMS Medical Corp.
-------------------------
BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical’s lead technology, MBP8298, is for the treatment of multiple sclerosis and is currently in a pivotal Phase II/III clinical trial across Canada and Europe. For further information please visit our website at www.biomsmedical.com.
This news release may contain certain forward-looking statements that reflect the current views and/or expectations of BioMS Medical with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.
BioMS Medical Corp.
CONTACT: Tony Hesby, Ryan Giese, Corporate Communications, BioMS MedicalCorp., (780) 413-7152, (780) 408-3040 Fax, E-mail: rgiese@biomsmedical.com,Internet: www.biomsmedical.com; James Smith, Investor Relations, (416)815-0700 ext. 229, (416) 815-0080 Fax, E-mail: jsmith@equicomgroup.com; Mr.Barry Mire, Investor Relations, Phone: (514) 939-3989; E-mail:bmire@renmarkfinancial.com
